T

    Takeda Pharmaceutical Co Ltd ADR (TAK)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NYSE

    $18.00
    -0.03 (-0.17%)

    Market Cap: $57.58B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    47%(15/32)
    Avg Surprise
    +2975.66%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$N/A
    Revenue Consensus
    $1.2T
    Range$1.1T - $1.2T
    6 analysts
    Dec 31, 2026
    EPS Consensus$N/A
    Revenue Consensus
    $1.2T
    Range$1.1T - $1.3T
    6 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-N/A---
    Sep 26EST
    		-N/A---
    Jun 26
    		$0.48$0.41+17.07%Beat-99.7%
    Mar 26
    		$-0.74N/AN/ABeat-226.6%
    Dec 25
    		$0.21N/AN/ABeat+339.1%
    Sep 25
    		$-0.03N/A-116.75%Miss-100.1%
    Jun 25
    		$151.00$0.20+75174.18%Beat+78423.1%
    Mar 25
    		$-0.23$-0.17-37.11%Miss-3401.5%
    Dec 24
    		$0.05N/A-92.41%Miss-99.9%
    Sep 24
    		$29.07N/A-66.76%Miss+287.5%
    Jun 24
    		$0.19$0.12+56.60%Beat-99.3%
    Mar 24
    		$-0.01N/A+54.23%Beat-108.8%
    Dec 23
    		$33.79$0.11+31042.86%Beat+11444.2%
    Sep 23
    		$-15.50$0.14-10856.42%Miss-177.4%
    Jun 23
    		$28.76$18.62+54.46%Beat-15.3%
    Mar 23
    		$0.07$0.05+46.53%Beat+373.1%
    Dec 22
    		$0.29$0.29+0.93%Beat+82.4%
    Sep 22
    		$20.03N/A-70.34%Miss+490.4%
    Jun 22
    		$33.97$59.27-42.69%Miss-46.9%
    Mar 22
    		$-0.03N/A-144.72%Miss-100.0%
    Dec 21
    		$0.16$0.22-27.21%Miss-99.5%
    Sep 21
    		$-5.13N/A-105.29%Miss-471.7%
    Jun 21
    		$64.00$95.00-32.63%Miss+142.9%
    Mar 21
    		$63.08$88.00-28.32%Miss+11369.1%
    Dec 20
    		$29.78N/A-71.64%Miss+892.7%
    Sep 20
    		$1.38N/A-98.66%Miss+762.5%
    Jun 20
    		$26.35N/A-69.00%Miss+43015.3%
    Mar 20
    		$0.55$-0.21+361.90%Beat+188.7%
    Dec 19
    		$3.00N/A-96.00%Miss+1272.4%
    Sep 19
    		$0.16$-0.21+176.19%Beat-41.5%
    Jun 19
    		$-0.06N/A+67.68%Beat-113.7%
    Mar 19
    		$-0.62$-0.36-72.22%Miss-97.3%
    Dec 18
    		$0.22$0.10+118.60%Beat-45.1%
    Sep 18
    		$0.27$0.23+18.96%Beat+74.3%
    Jun 18
    		$0.45$0.31+44.13%Beat-46.6%
    Mar 18
    		$-0.31$-0.37+15.08%Beat-10.4%
    Dec 17
    		$0.40N/AN/ABeat+68.9%
    Sep 17
    		$0.16N/AN/ABeat+4.7%
    Jun 17
    		$0.84N/AN/ABeat-
    Mar 17
    		$-0.28N/AN/ABeat-
    Dec 16
    		$0.24N/AN/ABeat-
    Sep 16
    		$0.15N/AN/ABeat-

    Dividends

    Dividend Metrics

    Yield3.50%
    Annual/Share$0.63
    Payout Ratio178.49%
    Frequency2
    Pay MonthsJul, Dec

    Growth

    3Y CAGR-3.21%
    5Y CAGR-6.78%
    View TAK's full dividend history

    Key Metrics

    Valuation
    P/E Ratio-228.72EV/EBITDA23.30x
    Price/FCF15.70xFCF Yield6.37%
    Profitability
    Profit Margin-3.54%Operating Margin16.50%
    ROE-2.26%ROIC3.22%
    Financial Health
    Debt/Equity0.65xInterest Coverage1.85x
    Current Ratio1.14xQuick Ratio0.62x
    Trading Statistics
    Beta0.10Avg Volume2.88M
    52-Week High$18.8952-Week Low$12.77

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$18.16
    SMA 20$17.71
    SMA 50$17.07
    SMA 200$16.55
    EMA 10$18.02
    EMA 20$17.79
    EMA 50$17.29
    EMA 200$16.46

    MACD

    Line: 0.32Signal: 0.33Hist: -0.02

    ADX

    ADX: 25.0+DI: 35.0-DI: 22.1

    Aroon & PSAR

    Aroon Up68.0
    Aroon Down24.0
    PSAR$17.92

    Bollinger Bands

    Upper Band$18.77
    Lower Band$16.64
    %B Position1203%(Upper)
    Band Width0.64

    RSI (14-Day)

    Neutral
    58.1

    Momentum Oscillators

    Stoch %K60.9
    Stoch %D68.3
    Williams %R-40.7
    ROC (10d)3.6%
    Momentum0.62
    CCI (20d)43.6
    MFI (14d)43.9

    Volatility Measures

    ATR (14d)$0.27(1.5%)
    StdDev (20d)0.53
    Hist Vol21.9%(Moderate)

    Volume Flow

    VWAP$18.00
    OBV85.3M
    AD Line-4.0B
    CMF (20d)0.047

    Volume Metrics

    Avg Vol (20d)2.9M
    Vol Ratio0.6x
    VWMA (20d)$17.55

    Pivot Points

    R3$18.26
    R2$18.18
    R1$18.11
    Pivot Point$18.03
    S1$17.96
    S2$17.88
    S3$17.81

    Advanced Oscillators

    TSI22.80
    Ultimate Osc52.0
    KST66.01

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$1219.90B$1114.65B$1213.21B$1112.80B$1106.68B$1053.40B$1144.12B$1176.04B$1207.99B$1050.87B$1111.19B$1043.09B
    Cost of Revenue$406.68B$570.84B$552.87B$380.06B$384.68B$382.10B$416.87B$394.31B$386.95B$387.33B$379.48B$343.58B
    Gross Profit$813.22B$543.81B$660.35B$732.74B$722.01B$671.30B$727.25B$781.73B$821.04B$663.54B$731.71B$699.51B
    Operating Expenses$611.81B$496.27B$466.28B$663.74B$537.44B$746.20B$660.31B$597.48B$654.71B$673.61B$626.79B$748.85B
    R&D$167.40B$198.91B$178.39B$161.48B$143.89B$216.00B$170.19B$175.56B$168.46B$195.86B$187.38B$183.95B
    SG&A$286.51B$292.00B$282.78B$253.55B$255.88B$295.87B$270.59B$268.28B$270.03B$285.23B$267.52B$252.95B
    Operating Income$201.42B$47.54B$194.06B$69.00B$184.57B$-74,900,000,000$66.94B$184.25B$166.33B$-10,069,000,000$104.91B$-49,341,000,000
    Interest Income$24.61B$189.15B$87.87B$44.40B$33.94B$32.37B$40.54B$4.12B$30.68B$34.81B$21.79B$46.64B
    Interest Expense$63.84B$44.45B$125.86B$83.14B$107.16B$330.20M$207.35M$68.45B$59.69B$317.81M$66.57B$401.37M
    Income Before Tax$162.72B$-53,443,096,000$136.28B$28.17B$150.63B$-107,300,000,000$26.41B$119.37B$136.60B$-47,522,000,000$61.26B$-95,980,000,000
    Income Tax Expense$49.46B$-28,740,469,000$30.67B$39.90B$26.35B$-4,200,000,000$2.57B$27.27B$41.30B$-44,528,000,000$-44,496,000,000$-48,009,000,000
    Net Income$113.20B$-24,765,767,000$105.51B$-11,802,000,000$124.24B$-103,200,000,000$23.79B$92.05B$95.25B$-3,018,000,000$105.72B$-48,030,000,000
    EBITDA$337.49B$157.89B$456.22B$316.47B$439.42B$181.27B$193.01B$380.28B$388.51B$259.24B$257.03B$202.28B
    EBIT$226.56B$-8,992,216,000$262.14B$111.31B$257.79B$-8,500,000,000$6.05B$187.83B$196.29B$156.03B$69.97B$-37,958,000,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    The Toll Booth on Biotech’s Highway: Why Halozyme’s Royalty Engine Could Make Patient Investors Rich

    Halozyme's ENHANZE platform is a toll booth on injectable biologics: partners develop drugs, HALO collects royalties on every dose sold across 10 commercialized products in 100+ global markets. Three major deals in 100 days: Elektrofi acquisition ($750M+ in Oct), Skye Bioscience (Jan 5), and Takeda (Jan 8) expand the royalty runway and add obesity/IBD market exposure. Margins look like software, not biotech: 84.6% gross, 59.3% operating, 48% FCF yield. Interest coverage of 43x means the business can absorb setbacks without existential risk. At $71.67, HALO trades ~24% below DCF-blended fair value (~$92.5) with a forward PEG of 0.3x. Analyst targets range $58-$92, with recent upgrades to $90 from TD Cowen and Benchmark. Elektrofi's Hypercon technology extends delivery-tech IP into the 2040s, addressing the key bear case around ENHANZE patent duration risk in the late 2020s. Buy zone: $71-74 (current). Strong add: $62-69. Very strong: $56-62. Trim at $96-101. Invalidation trigger: two consecutive quarters of FCF decline without explanation. Key catalyst: Earnings mid-late Feb 2026. Watch royalty growth trajectory, Takeda/Skye integration commentary, and Hypercon partner clinical development progress by year-end.

    Unknown Author
    •
    1/14/26
    •
    165
    Biotech
    value investing
    Healthcare Stocks
    Also mentions:
    TAK
    JNJ

    Government Contracts

    Gov Obligations (TTM)
    $0
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    N/A
    Active Awards
    0
    New Awards (TTM)
    0
    Avg Remaining Term
    N/A

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Takeda’s Orzeyful secured Japan MHLW approval for narcolepsy type 1

    Takeda's Orzeyful (oveporexton) has received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for treating narcolepsy type 1 in adults. This makes Orzeyful the first treatment in Japan to target the underlying cause of narcolepsy type 1, an oral orexin receptor 2 agonist discovered in Takeda’s laboratories. The approval follows positive results from global Phase III FirstLight and RadiantLight clinical trials, which demonstrated improvement in excessive daytime sleepiness and cataplexy.

    Pharmaceutical Technology•8/25/26•
    Bullish

    Takeda Pharmaceutical (TAK) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $TAK

    This article provides an overview of Takeda Pharmaceutical's (TAK) FDA approvals, PDUFA dates, and drug alerts for 2026, detailing regulatory milestones and clinical trial results for several key drugs like ORZEYFUL, TAK-279, TAK-881, and TAK-861. It highlights recent approvals, data presentations, and FDA acceptances, specifically noting the Japanese MHLW approval for ORZEYFUL for narcolepsy type 1. The article also addresses frequently asked questions regarding Takeda's FDA activities and the conditions targeted by their pipeline drugs.

    MarketBeat•8/24/26•
    Bullish

    Takeda Secures Japan Approval for Orzeyful to Treat Narcolepsy Type 1

    Takeda Pharmaceutical Company Limited has received approval in Japan for its drug Orzeyful (oveporexton) to treat Narcolepsy Type 1. This marks Orzeyful as the first treatment specifically targeting this condition in Japan. The approval highlights Takeda's continued efforts in the neuroscience field, following recent FDA approval for the same drug in the US.

    marketscreener.com•8/24/26•
    Bullish

    Andrew Stewart Plump Sells 19,651 Shares of Takeda Pharmaceutical (NYSE:TAK) Stock

    Andrew Stewart Plump, an insider at Takeda Pharmaceutical (NYSE:TAK), sold 19,651 shares of the company's stock for approximately $363,347 under a pre-arranged Rule 10b5-1 plan. This sale reduced his ownership by 6.99%, bringing his total to 261,656 shares. The company's shares are trading near their 52-week high, and Takeda recently reported strong quarterly earnings, surpassing analyst estimates for both EPS and revenue, while analyst sentiment remains mixed with an average "Hold" rating.

    MarketBeat•8/21/26•
    Neutral

    Insider Selling: Takeda Pharmaceutical (NYSE:TAK) Insider Sells 12,980 Shares

    Takeda Pharmaceutical insider Nicola Deidre Petal Greenway sold 12,980 shares of the company's stock for a total of $235,067.80. This transaction reduced her holdings by 24.48%, leaving her with 40,049 shares. The sale occurred on August 18th at an average price of $18.11, following a previous sale on August 10th.

    MarketBeat•8/19/26•
    Neutral

    Frequently Asked Questions About TAK

    What is TAK's current dividend yield?
    Takeda Pharmaceutical Co Ltd ADR (TAK) has a current dividend yield of 3.50%.
    Does TAK pay dividends?
    Yes, Takeda Pharmaceutical Co Ltd ADR pays dividends with a current yield of 3.50%.
    What is TAK's market cap?
    Takeda Pharmaceutical Co Ltd ADR (TAK) has a market capitalization of $57.58B with a current stock price of $18.00.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In